About this trial
Acute respiratory distress syndrome (ARDS) is a life-threatening condition requiring respiratory support to maintain oxygenation. Very few biomarkers about ARDS have been identified but none of them has a sufficient specificity or sensitivity to characterize by itself the severity of lung condition. Investigators hypothesize that there is considerable change occurring in metabolic profiles in mild, moderate, and severe ARDS in comparison to healthy cohort, which can be detectable through serum analysis using NMR based metabolomics study. This research would help to understand metabolomics kinetics during the ARDS disease progression. Overall, NMR-based metabolomics study would provide an insight into the mediators involved in pathogenesis and progression of ARDS.
Eligibility criteria
Qualifiers
Critically ill adult patients having mild ARDS with onset less than 72 hours
Disqualifiers
Age less than 18 years or more than 65 years
Expected survival <72 hours
Refusal from family member
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lead sponsor
Centre of BioMedical Research, India
Collaborator